CLAIMS

1. A medical product comprising a dry powder dose of tiotropium directly loaded into a container, wherein

a dry, high barrier seal constitutes the container;

the high barrier seal of the container prevents ingress of moisture whereby the original fine particle fraction of the powder dose is preserved, and

the dry powder dose in the container is adapted for administration by a dry powder inhaler.

2. The medical product according to claims 1, wherein

administration of the dry powder dose is performed by inhalation from a dry powder inhaler providing a prolonged dose delivery.

3. The medical product according to claims 1, wherein

the tiotropium substance consists of one or more physiologically acceptable salts of tiotropium.

4. The medical product according to claims 1, wherein

an included excipient is lactose.

5. The medical product according to claims 1, wherein

formed or flat aluminum foils, optionally laminated with polymers, constitute the dry, high barrier seal.

6. The medical product according to claims 1, wherein

a cavity molded from a polymer material selected to give the container high barrier seal properties constitutes the container.

7. The medical product according to claims 1, wherein

a cavity molded from a polymer material together with a high barrier seal constitute the container providing it with high barrier seal properties.

8. The medical product according to claims 1, wherein the container is a part of a dry powder inhaler.

9. The medical product according to claims 1, wherein the container is a separate part adapted for insertion into a dry powder inhaler

10. The medical product according to claims 1, wherein the container is a separate part comprising a primary part adapted for insertion into a dry powder inhaler and a secondary part enclosing the primary part in a moisture-tight package.

11. The medical product according to claims 1, wherein the medical product is intended for use in the treatment of respiratory disorders.

12. A pharmaceutical composition comprising tiotropium or a physiologically acceptable salt thereof and a physiologically acceptable excipient, wherein the composition is directly loaded and sealed into a dry, moisture-tight package or dry, high barrier container in order to preserve the original fine particle fraction of the composition.

13. The pharmaceutical composition according to claim 12, wherein administration of the combination dry powder dose is performed by inhalation from a dry powder inhaler providing a prolonged dose delivery.

14. The pharmaceutical composition according to claim 12, wherein

the tiotropium comprises one or more physiologically acceptable salts of tiotropium.

15. The pharmaceutical composition according to claim 12, wherein an included excipient is lactose.

16. The pharmaceutical composition according to claim 12, wherein formed or flat aluminum foils, optionally laminated with polymers, constitute the dry, moisture-tight package or dry, high barrier container.

17. The pharmaceutical composition according to claim 12, wherein a cavity molded from a polymer material with high barrier seal properties forms the dry, moisture-tight package or dry, high barrier container.

18. A pharmaceutical composition according to claim 12, wherein a cavity molded from a polymer material together with a high barrier seal constitute the dry, moisture-tight package or dry, high barrier container, thereby giving the package or container high barrier seal properties.

19. The pharmaceutical composition according to claim 12, wherein the dry, moisture-tight package or dry, high barrier container constitutes a part of a dry powder inhaler.

20. The pharmaceutical composition according to claim 12, wherein the dry, moisture-tight package or dry, high barrier container is a separate part adapted for insertion into a dry powder inhaler.

21. The pharmaceutical composition according to claim 12, wherein the dry, moisture-tight package or dry, high barrier container is a separate part comprising a primary package adapted for insertion into a dry powder inhaler, and a secondary moisture-tight package or container enclosing the primary package.

22. The pharmaceutical composition according to claim 12, wherein the pharmaceutical composition is for a use in the treatment of a respiratory disorder.

23. A medical product comprising tiotropium and separate or together with at least one additional active pharmaceutical ingredient and optionally including exicipients in a dry powder medical combination dose directly loaded into a container, wherein

a dry, high barrier seal constitutes the container;

the high barrier seal of the container prevents ingress of moisture whereby the original fine particle fraction of the combination dose is preserved;

the combination dose is adapted for administration by a dry powder inhaler, and

the at least one additional active pharmaceutical ingredient is selected from the following groups of substances: inhalable steroids, nicotinamide derivatives, beta-agonists, beta-mimetics, anti-histamines, adenosine A2A receptors, PDE4 inhibitors, dopamine D2 receptor agonists.

24. The medical product according to claims 23, wherein

administration of the dry powder dose is performed by inhalation from a dry powder inhaler providing a prolonged dose delivery.

24. The medical product according to claims 23, wherein

the tiotropium substance consists of one or more physiologically acceptable salts of tiotropium.

25. The medical product according to claims 23, wherein

an included excipient is lactose.

26. The medical product according to claims 23, wherein

formed or flat aluminum foils, optionally laminated with polymers, constitute the dry, high barrier seal.

27. The medical product according to claims 23, wherein

a cavity molded from a polymer material selected to give the container high barrier seal properties constitutes the container.

28. The medical product according to claims 23, wherein

a cavity molded from a polymer material together with a high barrier seal constitute the container providing it with high barrier seal properties.

29. The medical product according to claims 23, wherein

the container is a part of a dry powder inhaler.

30. The medical product according to claims 23, wherein

the container is a separate part adapted for insertion into a dry powder inhaler

31. The medical product according to claims 23, wherein

the container is a separate part comprising a primary part adapted for insertion into a dry powder inhaler and a secondary part enclosing the primary part in a moisture-tight package.

32. The medical product according to claims 23, wherein

the medical product is intended for use in the treatment of respiratory disorders.

33. A pharmaceutical composition comprising tiotropium or a physiologically acceptable salt thereof and separate or together with at least one active pharmaceutical ingredient, optionally including physiologically acceptable excipients in a combination dry powder dose, wherein

the combination dry powder dose is directly loaded and sealed into a dry, moisture-tight package or dry, high barrier container in order to preserve the original fine particle fraction (FPF) of the composition;

the at least one active pharmaceutical ingredient is selected from the following groups of substances: inhalable steroids, nicotinamide derivatives, beta antagonists, beta-mimetics, anti-histamines, adenosine A2A receptors, PDE4 inhibitors, dopamine D2 receptor agonists.

34. The pharmaceutical composition according to claim 33, wherein administration of the combination dry powder dose is performed by inhalation from a dry powder inhaler providing a prolonged dose delivery.

35. The pharmaceutical composition according to claim 33, wherein the tiotropium comprises one or more physiologically acceptable salts of tiotropium.

36. The pharmaceutical composition according to claim 33, wherein an included excipient is lactose.

37. The pharmaceutical composition according to claim 33, wherein formed or flat aluminum foils, optionally laminated with polymers, constitute the dry, moisture-tight package or dry, high barrier container.

38. The pharmaceutical composition according to claim 33, wherein a cavity molded from a polymer material with high barrier seal properties forms the dry, moisture-tight package or dry, high barrier container.

39. A pharmaceutical composition according to claim 33, wherein a cavity molded from a polymer material together with a high barrier seal constitute the dry, moisture-tight package or dry, high barrier container, thereby giving the package or container high barrier seal properties.

40. The pharmaceutical composition according to claim 33, wherein the dry, moisture-tight package or dry, high barrier container constitutes a part of a dry powder inhaler.

41. The pharmaceutical composition according to claim 33, wherein the dry, moisture-tight package or dry, high barrier container is a separate part adapted for insertion into a dry powder inhaler.

42. The pharmaceutical composition according to claim 33, wherein the dry, moisture-tight package or dry, high barrier container is a separate part comprising a primary package adapted for insertion into a dry powder inhaler, and a secondary moisture-tight package or container enclosing the primary package.

43. The pharmaceutical composition according to claim 33, wherein the pharmaceutical composition is for a use in the treatment of a respiratory disorder.